VHIRhttp://www.vhir.org/salapremsa/noticies/noticies_paginacio.asp?page=1&mv1=5&mv2=3es-esIRHUV15Industex employees visit VHIR to see the results of their donation (29/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=98&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0098\2015_0098_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Employees from the Catalan company of innovative products, Industex, returned to Vall d’Hebron Institute of Research (VHIR) in order to see the results of the 50,000 euros donation that co-funded in 2012 the first INCOMED call. The staff visited the lab of Dr. Rosanna Paciucci, researcher from the Translational Biomedical Research in Urology Group. In this lab also works Dr. Carlos Fernández, who received the INCOMED grant thanks to Industex. In Dr. Paciucci’s lab, they investigate prostate cancer, which is the most frequent cancer in men in western Countries and the second leading cause of death for cancer in Europe. The advanced metastatic cancer is still a major unresolved problem. In their lab, they have investigated the actions of the oncogenic protein prostate tumor overexpressed-1, PTOV1, that they discovered for its high expression in aggressive tumors and significantly associated with poor prognosis in prostate, breast, bladder, ovary and liver cancers. They have recently described two mechanisms of action for this protein that are implicated in prostate cancer progression. Thanks to the collaboration with Industex, they have discovered an additional action for this protein that is linked to its ability to repress a major tumor suppressor gene. These results further confirm PTOV1 as a significant target for future, more specific therapies in metastatic prostate cancer. Industex employees also visited VHIR in 2013.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Fri, 29 May 2015 00:00:00 GMTPROSICS and Interarts launch Diverxual, a platform of resources for sexual and reproductive health (28/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=97&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0097\2015_0097_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The project Decides España, developed by the International Health Programme of the Catalan Institute of Health (PROSICS) and Interarts, with the participation of Dr. Jordi Gómez, from the infectious diseases group at VHIR, has launched the webpage Diverxual, with the aim to provide to health professionals the knowledge and practical tools related with sexual and reproductive health. The platform offers specialized workshops, training videos, guidelines and official health protocols related to this field. The website is addressed to professionals working in public and private associations or entities who give support to immigrants in the access to sexual and reproductive health. Diverxual is part of the project Decides España, whose aim is to improve equity in the access to and exercise of sexual and reproductive rights of young and women of migrant origin in Spain. PROSICS professionals did an assessment of the situation in Spain, which concluded that it was necessary to develop new educational and informative materials on affective sexual and reproductive health integrating the approach of equity, gender and cultural specificities. Decides España is project co-funded by the Financial Mechanism of the European Economic Area which aims at contributing to the reduction of economic and social inequalities, and strengthening links between donor (Iceland, Liechtenstein and Norway) and beneficiary countries (17 EU Member States). The Plataforma de ONG de Acción Social is the Operational Unit of the Active Citizenship Programme endowed with EUR 4.6 million to support the contribution of NGOs to social justice and sustainable development. You can follow the Active Citizenship Programme on Facebook and Twitter. </td></tr></table>comunica@vhir.org (VHIR)Thu, 28 May 2015 00:00:00 GMTVHIR trains science teachers in hepatitis B and C virus (27/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=96&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0096\2015_0096_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> 10 science teachers from several Catalan high-schools participated in the course “The hepatitis B and C virus: prevention, knowledge and innovations in the treatments”, organized by doctors Josep Quer and Francisco Rodríguez-Frías, researchers from the Hepatic Diseases at Vall d’Hebron Institute of Research (VHIR), in the framework of the Teachers and Science programme by the Catalunya La Pedrera Foundation. The duration of the course was 12 hours in which researchers introduced the main concepts of virology: which is the vital cycle of the virus, the routes of transmission, the risk of infection depending on the habits, the new methods of study based on massive sequencing techniques and the latest advances on research in this field. Besides the theory, Dr. Quer presented to them two educational games, that he designed together with the Spanish Society of Virology, in order to translate to the schools the knowledge about these virus: one of the games is called Virópolis, and it is available online, and the other one, Epidemia vir(TU)al, will be available soon as a mobile app. Teachers also visited the clinical labs of Vall d’Hebron University Hospital, where everyday nearly 6,000 blood samples from all Barcelona are analyzed. Nowadays, more than half of the deaths by infections worldwide are caused by the hepatitis virus, specifically the type C. The climate change and the aggressions to the ecology, as well as the geographical location of Spain put us in a zone of risk of viral emerging or re-emerging diseases. According to the World Health Organization, viral diseases are the cause of 2/3 of the medical consultations by infectious processes. </td></tr></table>comunica@vhir.org (VHIR)Wed, 27 May 2015 00:00:00 GMTThe 3rd DiR-Guàrdia Urbana race will raise funds for research in child cancer (26/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=22&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0022\2015_0022_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The third edition of the DiR-Guàrdia Urbana race will take place in the Avinguda Diagonal, in Barcelona, on May 31st. Participants will run 10km of the entire Diagonal, with two messages: “for you maybe is just a race, but for them is their life” and “run and help us to investigate for children with cancer”. Part of the funds collected in the race will be donated to the Translational Research in Child Cancer group at Vall d’Hebron Institute of Research (VHIR). The race will start at 8.30 AM at Palau Reial and the finish line will be located at Passeig Garcia Faria. Registrations are already open on www.dir.cat and in any of the gyms of the group. The mission of the Translational Research in Child Cancer group is to improve the diagnosis and treatments available for these diseases. </td></tr></table>comunica@vhir.org (VHIR)Tue, 26 May 2015 00:00:00 GMTVHIR participates in two studies that could change the surgical protocols of hip fractures in the elderly (25/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=93&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0093\2015_0093_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Reconstructive Surgery of the Locomotor System group at Vall d’Hebron Institute of Research (VHIR), led by Dr. César Galo García-Fontecha, and the Traumatic Unit of the Traumatology Area at Vall d’Hebron University Hospital, headed by Dr. Vicente Molero, participate in two ongoing studies that could change the surgical protocols of hip fractures in the elderly. The studies are multicenter, prospective and randomized, and coordinated by Dr. Mohit Bhandari, from the McMaster University in Ontario, Canada. According to Dr. García-Fontecha, “both studies could mark a milestone for the orthopedics community, because they will probably change the treatment of fragile old people with comorbidities that suffer hip fractures”.&nbsp; Nowadays, between the 20 and 30 per cent of patients with hip fractures die during the first year. In addition, hip fractures are associated to a high risk of complications, re-operations and disability. The first study, called HeEALTH and led by Ernesto Guerra and Jordi Teixidor, compares the outcomes of the bipolar prosthesis versus total prosthesis in femoral neck fractures. The objectives of the project are to improve the functional results and avoid complications and reoperations. On the other side, the Hip Attack study, led by Ernesto Guerra and Jordi Tomàs, examines whether 'accelerated' surgery (carried out in the first 6 hours after the diagnosis) results in better recovery, better outcomes, and less deaths, when compared to current practice (currently, most people have surgery within 48-72 hours). However, if accelerated surgery is shown to be better, as it happened in the pilot study, Dr. Guerra says that “this could entirely change the way hip fracture patients are treated, because we will have to do codes of procedures such as the Stroke Code or the Myocardial Infarction Code, in which a fast intervention is essential for saving lives”.&nbsp;&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Mon, 25 May 2015 00:00:00 GMTMore than 2,000 people celebrated the 20th birthday of the research at Vall d'Hebron with a solidarity party (23/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=79&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0079\2015_0079_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On Saturday we celebrated the Party of the Research at Vall d’Hebron, at the Pavelló Olímpics Vall d’Hebron, the first organized by a research institute of a hospital in Catalonia, where more than 2,000 people attended. The popular celebration closed the 20th anniversary of the Vall d’Hebron Research Institute (VHIR) and was the preamble of the 60th birthday of the University Hospital Vall d’Hebron. The objective of the party was to make people aware of the importance of research and also to connect the society with the best biomedical research. The celebration was promoted by Andrés Iniesta, VHIR’s ambassador, Tomàs Molina, who participated as a Friend of VHIR, and Judit Mascó, and was possible thanks to La Caixa, Sanofi and Palex. From 10am to 12:30am and from 3pm to 5pm in the Sala de la Recerca inside the Pavelló, VHIR’s researchers offered scientific workshops and showed the best scientific photographs from the photo competition we do every year. Furthermore, everybody could see what the most important research lines in the Hospital are, looking at the posters we put on the walls. The first people that came, at 10am, found some chocolate to drink outside the Pavelló. Then, from 10.30am to 12.30am they enjoyed the Radio Flaixbac’s DJ’s workshop, with Andreu Presas, and also a </td></tr></table>comunica@vhir.org (VHIR)Sat, 23 May 2015 00:00:00 GMTRaimon performed at the Teatre Principal d'Olot to raise funds for the research in VHIR (19/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=91&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0091\2015_0091_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Last Friday, the 8th of May, the singer-songwriter Raimon made a solidarity concert at the Teatre Principal d’Olot to inaugurate his tour. The concert, wich was organized by the Albert Bosch Foundation, was a success and the tickets sold-out. The money collected will be destined for the research projects of the group “Translational Research in Child Cancer” at Vall d’Hebron Research Institute (VHIR). He played old songs like ‘Diguem no’ or ‘Com un puny’, but new ones too. He also singed poems from Ausiàs March, Roís de Corella, Jaume Roig o Salvador Espriu. The concert was so special because he hadn’t performed in Olot for 20 years. The money collected will impulse the research group headed by Dr. Sánchez de Toledo. From VHIR we want to thank the Albert Bosch Foundation, who has collaborated many times with us, for the initiative. </td></tr></table>comunica@vhir.org (VHIR)Tue, 19 May 2015 00:00:00 GMTVHIR celebrates the first scientific retreat to talk about the science made at Vall d'Hebron (15/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=90&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0090\2015_0090_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Prullans, in la Cerdanya, hold of the first scientific retreat of the Vall d’Hebron Institut de Recerca (VHIR). In the meeting participated group leaders, principal investigators, young researchers and the heads of the VHIR's structural units, with the aim to discuss the present and the future of the research in the Institute and the outlines of the new strategic plan for the period 2016-2020. During the meeting, 15 research groups presented their research lines and landmarks, in order to disseminate their work, facilitate the interactions and share common lines. The second day began with a speaking about the VHIR’s strategic positioning and the research transversal programs that will be implemented in the future. Among these programs, three were presented: the Nanomedicine and Advanced Therapies Centre, headed by Dr Simó Schwartz, the Spina Bifida Program, coordinated by Dr. Elena Carreras, and the Translational Immunology and Systems, headed by Dr. Ricard Pujol. All the researchers also participated in several focus groups to discuss the main points to take into account to prepare the Institute’s strategic plan for the next five years. Retreat pictures </td></tr></table>comunica@vhir.org (VHIR)Fri, 15 May 2015 00:00:00 GMTVall d'Hebron clausura las XIII Jornadas Anuales del Síndrome de Fatiga Crónica (14/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=89&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0089\2015_0089_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Por treceavo año consecutivo se han celebrado, los días 13 y 14 de Mayo de 2015, la Jornada del Síndrome de fatiga crónica en el salón de actos del Pabellón Docente del Hospital Universitario Vall d'Hebron de Barcelona, coordinada por el Dr. José Alegre, jefe del grupo de investigación de esta enfermedad en el Vall d’Hebron Institut de Recerca (VHIR). La jornada, considerada de referencia a nivel nacional, ha contado con especialistas de primer nivel que han expuesto los temas más relevantes en relación con este complejo síndrome que comporta una importante limitación funcional, tanto en las actividades de predominio físico como intelectual, en forma de incapacidad laboral en el adulto y fracaso escolar en el niño. En el momento actual se están dando pasos de gigante en el cocimiento de la severidad de la fatiga crónica en todo su contexto. Esto es posible gracias a la ayuda de las nuevas tecnologías y la inclusión de grupos de trabajo multidisciplinares de biotecnólogos, ingenieros y matématicos que utilizan programas informáticos utilizando dispositivos móviles, estudios de neuroimagen, fisiológicos y de citometría de flujo funcional. El eje central de las jornadas científicas se ha centrado en los avances en el estudio de la disfunción del sistema nervioso autónomo en el síndrome de fatiga crónica, con la utilización de elementos de medida no agresivos, y la introducción de programas informáticos en los dispositivos móviles. El estudio lo lideran diversos investigadores clínicos y  básicos del VHIR, y profesionales del Instituto Catalán de Farmacología, la Universitat Autonòma de Barcelona, la Universidad Politécnica de Cataluña, la Fundación Futbol Club Barcelona y la empresa Health &amp; Sportlab. Por otro lado, en las jornadas se han comentado aspectos relevantes de la valoración de la severidad de la intolerancia al ejercicio físico en esta enfermedad, con técnicas ergométricas y de biología molecular. También se han presentado las aportaciones de la neuroimagen y la neurobiologia en el estudio de la disfunción cognitiva, la importancia de la investigación del fenotipado linfoide en la valoración de la disfunción inmune y el estudio de los fenómenos asociados, tales como el mayor riesgo de síndrome metabólico y del desarrollo posterior de neoplasias. Entre medio de las dos sesiones, se presentó  la Asociación Dolfa, la primera asociación en España para fomentar la investigación clínica y básica en el síndrome de fatiga crónica en niños y adolescentes. La jornada ha culminado con un seminario a cargo de la Dra. Zoe M. Gotts, investigadora postdoctoral del Newcastle Fatigue Research Center, del Reino Unido. Gotts es una autoridad europea en este campo, y está especializada en el impacto de la disfunción del sueño en la fatiga crónica. </td></tr></table>comunica@vhir.org (VHIR)Thu, 14 May 2015 00:00:00 GMT El Dr. Josep Sánchez de Toledo rep la Medalla Josep Trueta en reconeixement a la seva tasca per al progrés i millora de la sanitat (13/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=88&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0088\2015_0088_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> El Dr. Josep Sánchez de Toledo, cap del grup de Recerca Translacional en el Càncer a la Infància i l’Adolescència del Vall d’Hebron Institut de Recerca (VHIR) i cap del Servei d’Oncologia i Hematologia Pediàtrica de l’Hospital Maternoinfantil Vall d’Hebron, ha rebut aquest dimarts la Medalla Josep Trueta al mèrit sanitari en un acte al Palau de la Generalitat. Sánchez de Toledo ha estat una de les 13 figures de la sanitat catalana que han vist reconeguda aquest vespre la seva tasca i els serveis prestats amb vista al progrés i la millora de la sanitat. Llicenciat en medicina i cirurgia a la Universitat Autònoma de Barcelona l’any 1974, el Dr. Sánchez de Toledo és especialista en Pediatria i un dels pioners en el desenvolupament de l’assistència i la recerca en el càncer a la infància. Ha estat president de la Sociedad Española de Oncología Pediátrica i de la seva fundació. Va impulsar la creació del Registre Nacional de Càncer Infantil i del registre català. El Dr. Josep Sánchez de Toledo combina el seu treball clínic en infants amb tumors i trasplantaments de medul·la òssia amb la més avançada recerca en càncer infantil. Actualment, a més de ser cap del seu grup, és membre del Consell Científic Intern del VHIR. També forma part del Comitè Científic de l’Associació Espanyola Contra el Càncer a Catalunya (AECC) i és el president del Comitè Científic de la Federació Oncològica de Catalunya. És membre de diverses societats científiques nacionals i internacionals i presideix la Comissió de Tumors de l’Hospital Vall d’Hebron i de la Comissió Assessora del Pla director d’oncologia de Catalunya. L’any 2012 va rebre el Premi a l’Excel·lència Professional del Col·legi de Metges de Barcelona i el 2013 va ser guardonat com a Català de l’Any 2012, premi que atorguen El Periódico de Catalunya i Televisió de Catalunya. El Servei d’Oncologia i Hematologia Pediàtrica de l’Hospital és capdavanter en el desenvolupament dels trasplantaments de progenitors hematopoètics en nens. L’any 2012 va obtenir l’acreditació internacional JACIE, que distingeix la qualitat assistencial, i l’any 2013 el premi Best in Class al millor servei d’Oncologia de l’Estat i l’any següent el Best in Class al millor servei de Trasplantaments. </td></tr></table>comunica@vhir.org (VHIR)Wed, 13 May 2015 00:00:00 GMTÉxito de las VIII Jornadas de Salud Internacional (12/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=87&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0087\2015_0087_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Más de 160 profesionales participaron en las VIII Jornadas de Salud Internacional celebradas en Barcelona del 7 al 8 de mayo y organizadas por investigadores y médicos del Vall d'Hebron y el Programa de Salud Internacional del Institut Català de la Salut (PROSICS). Durante dos días pudieron compartir información actualizada sobre vacunaciones y otros temas de interés sobre la especialización en salud internacional. Más concretamente, los profesionales hablaron sobre las novedades en vacunas para la enfermedad del ébola y el VIH o el dengue, los últimos brotes que han habido, y la importancia de la salud comunitaria en personas inmigradas, entre otras cuestiones. Anualmente, las unidades de salud internacional del ICS realizan unas 30.000 visitas de atención al viajero y dispensan más de 60.000 vacunas. El grupo de Enfermedades Infecciosas del VHIR, liderado por el Dr. Benito Almirante, está especializado en patologías internacionales como el Chagas, la malaria y la tuberculosis. </td></tr></table>comunica@vhir.org (VHIR)Tue, 12 May 2015 00:00:00 GMTResearchers identify a mechanism involved in the resistance to antitumor treatment (11/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=84&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0084\2015_0084_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the Molecular Pathology group at Vall d’Hebron Research Institute (VHIR), headed by Dr. Santiago Ramon y Cajal, have discovered that the phosphorylation of a protein, elF4E, confers resistance to cell stress, including the treatments that damage DNA, like cisplatin. The results of the study have been published in PLOS ONE. After a decade studying the signaling factors in in vitro models, researchers observed that high levels of 4EBP1 and EIF4E phosphorylated are associated with more aggressive tumors and a worse prognostic. Seeing these unexpected results, researchers from VHIR decided to start this study to analyze the role of the elF4E phospholylation and its implication in the resistance to agents that produce cell stress, like gene damage. With the collaboration of Dr Nahum Sonenberg’s group, from the University of McGill in Montreal (Canada), VHIR’s team carried out in vitro and murine models with several molecular approaches. With these models, as Dr Ramon y Cajal said “we have seen that blocking the elF4E phosphorylation, genetically or with chemical inhibitors, we cells become more sensitive to the classic treatment with chemotherapy”.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; With these results, the study’s lead author says that the door to optimize the standard chemotherapy treatment has been opened: “if we combine the chemotherapy of cytotoxic agents (like cisplatin) with selective inhibitors of these kinases, that don’t have relevant side effects, patients will suffer fewer side effects”. Additionally, the cytotoxic dose will be reduced and therapeutic effect increased. At present, there are two types of treatments available to fight against tumor cells: the cytotoxic treatments, which have a powerful antitumor effect but present many side effects, and the treatments with specific inhibitors for punctual genetic alterations, which are very selective and have fewer side effects. Nevertheless, tumor cells have many molecular alterations, and tumors usually become resistant to the specific inhibitors therapy. Now, together with the Organic Chemistry group from the Instituto Químico de Sarrià, VHIR researchers are trying to find new MNK kinase inhibitors, which would be more selective and effective, in order to potentiate the antitumor effect of the chemotherapy treatment with cytotoxic agents. </td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTResolution of the 20 finalist projects of the VHIR's Innovation Contest in Health (11/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=85&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0085\2015_0085_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Knowledge Transfer and Innovation Unit has just published the list of the 20 finalists of the VHIR’s Innovation Contest. Projects from biomedical research studies: - Gene Therapy for MNGIE using a new orphan drug consisting of an adeno-associated vector carrying TYMP. Vall d’Hebron Institut de Recerca (VHIR). - Pushing Myc inhibition to the clinic using cell penetrating peptides. Vall d’Hebron Institut d’Oncologia (VHIO). - Desarrollo de un kit de biomarcadores mitocondriales en sangre para el diagnóstico precoz del Alzheimer. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). - Desarrollo de un Chip Microfluídico para la Detección Precoz de Malaria. Vall d’Hebron Institut de Recerca (VHIR). - Detecció de la Neuropilina-1 (NRP-1) en l'orina com a biomarcador de pronòstic en la nefritis lúpica. Vall d’Hebron Institut de Recerca (VHIR) y Centro Superior de Investigaciones Científicas (CSIC). - Cardiopatch: Bio-Pegats digitals per al seguiment dels nounats amb cardiopaties. Vall d’Hebron Institut de Recerca (VHIR) y Centro Superior de Investigaciones Científicas (CSIC). - Ús d’un mètode per al mesurament d'ApoJ-Glicosilada per a la detecció precoç i l’estratificació de pacients amb infart agut de miocardi. Hospital de Sant Pau e Institut Català de Ciències Cardiovasculars (ICCC). - CeliFast, Rapid diagnosis of celiac disease at point of care based on magneto platforms. Hospital Germans Trias i Pujol. <p style=" text-align: left; text-indent</td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTVHIR participates in activities for the International Fibromyalgia and Chronic Fatigue Syndrome Awareness Day (11/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=86&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0086\2015_0086_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The 12th of May, has been designated as the International Fibromyalgia and Chronic Fatigue Syndrome/Encephalomyelitis Myalgic (CFS/ME) Awareness Day. The Chronic Fatigue Research Group at Vall d’Hebron Research Institute (VHIR), led by Dr José Alegre, is organizing a series of events in order to raise funds for CFS/ME research. With the same objective, the Foundation of patients affected by Fibromyalgia and CFS/ME and the IrsiCaixa Foundation have prepared a fundraising auction that will take place this Tuesday at 5:30 PM at the Pedrera’s Auditorium in Barcelona. 2015 CFS/ME Advances Day  Dr José Alegre coordinates again these sessions that will be held on the 13th of May at the Pabelló Docent Auditorium at the Vall d’Hebron Hospital, from 11 AM to 7 PM. The sessions are aimed to professionals, administration, associations and foundations of patients affected by Fibromyalgia, CFS/ME and Multiple Chemical Sensitivity, and have the objective to insight into the last advances in these conditions. The topics that will be discussed are research on exercise intolerance, study of the autonomic dysfunction and the impact of the comorbidity in the CFS/ME. VHIR’s Seminar Dr. Zoe M. Gotts, of the Newcastle Fatigue Research Centre, U.K. will present the seminar “Sleeping through fatigue”, on the 14th of May at 3:30 PM in the Conference Room on the ground floor at the General Area of Vall d’Hebron Hospital. The researcher will share last research in sleeping disorders in CFS/ME patients, which her group has been carrying out in recent years. Charity Concert La Contemporània will celebrate its 20th birthday on the 14th of May at 9PM doing a charity concert in the Pabelló Docent at Vall d’Hebron Hospital. The concert, called “Vint Tocats”, will go over the copla’s history, presenting funny proposals.&nbsp; The tickets will be offered for sale the same day in the place of the concert, and will cost 10 Euros. It is recommended not wearing any kind of cologne or perfumes to respect patients affected by multiple chemical sensitivity. Charity Art Auction <span style=" font-size: 8pt; font-family: 'Verdan</td></tr></table>comunica@vhir.org (VHIR)Mon, 11 May 2015 00:00:00 GMTThe Research Group on Neuromuscular and Mitochondrial Diseases is investigating to improve Antonio's quality of life (08/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=82&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0082\2015_0082_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Antonio is a three-year-old child who has a rare disease called mitochondrial myopathy due to thymidine kinase 2 (TK2) deficiency. This is a genetic disease that affects very few people in the world. The Research Group on Neuromuscular and Mitochondrial Diseases of VHIR, which studies and seeks for new treatments for this and other related diseases, made the genetic diagnose of Antonio and is helping to better understand the illness in order to improve the quality of life of these patients. The disease that Antonio suffers is caused by a genetic defect leading to protein TK2 deficiency. This protein is very important because is responsible for producing and maintaining the DNA from mitochondria, which are the intracellular elements providing energy to the cell, among other important roles. As a consequence of TK2 deficiency, patients are lacking two of the nucleotides that form the mitochondrial DNA, which affects several organs of the patients. Specifically, patients have problems in the function and development of their muscles, and their mobility and respiratory function can be compromised. For the moment, only one expensive treatment has been proposed to improve the quality of life of these patients. This treatment is based on the administration of the missing nucleotides. But now, the Research Group on Neuromuscular and Mitochondrial Diseases of VHIR, with Dr Ramon Martí as principal investigator, has suggested an alternative therapy, which is cheaper than the other, and is based on the administration of the nucleotides’ precursors: the nucleosides. As the doctor said: "up to now, the experimental facts indicate this alternative treatment is as efficient as the previous one". Importantly, production of nucleosides is significantly cheaper, which would help assuring all patients get access to the therapy. Antonio is trying this new therapy and, so far, results are as good as expected. Antonio’s parents have developed a platform with a website to raise awareness of the disease and to collect money to guarantee Antonio’s treatment and to fund research on the disease. Before long, on the 30th of May, they are going to inaugurate a solidarity photograph exhibition in order to raise funds to support the investigation carried out by the Research Group on Neuromuscular and Mitochondrial Diseases. These resources are going to be invested in the research on this disease and to develop therapeutic approaches to improve the quality of life of Antonio and all other patients suffering from TK2 deficiency.&nbsp;&nbsp; This is the exhibition's poster. </td></tr></table>comunica@vhir.org (VHIR)Fri, 8 May 2015 00:00:00 GMTGinger bread signature chocolate to fight against ovarian cancer (07/05/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=81&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0081\2015_0081_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> To celebrate the Ovarian Cancer World Day, on the 8th of May, the Gynecology Service in Vall d’Hebron University Hospital and the Biomedical research group in Vall d’Hebron Research Institute (VHIR) have started a campaign to raise awareness of the disease in a different way. For that reason, and seeing the last year’s success, they have the collaboration of Daniel Jordà (Panes Creativos) and Oriol Balaguer, who have recuperate the traditional bread and chocolate with a solidarity objective: sell it with a symbolic prize (2 Euros) to raise awareness of the disease and fundraise for the research. Both bakery artists from Barcelona have created, specifically, for the Ovarian Cancer World Day a piece of bread made off ginger and chocolate, two helpful ingredients to prevent this kind of cancer. The bread has been created using equilibrated ingredients by Daniel Jordà, who was inspirited in the Frances brioche. The chocolate, made by Oriol Balaguer has a vanilla taste and a soft texture. The creation will be sold the 8th of May in the Arcasa cafes of the Vall d’Hebron Hospital, in both establishments of the authors, in the Boqueria Market and in the BCNandCAKE shops that are attached to the campaign. A part from the bread and chocolate, solidarity bracelets are offered for sale to collect money for the research. These bracelets have been created by&nbsp; Samburu Accessoriesfor the occasion and can be purchased for 5 Euros. On the 8th of May, there are going to be different informative points in the halls of the Maternal and Child area and the General area of the Hospital Vall d’Hebron. The researchers from VHIR and from the Gynecology Service of the Hospital are going to do the awareness campaign, with the collaboration of the Asociación de Afectados por Cáncer de Ovario (ASACO). They are going to give stickers with the slogan of the campaign: “Una voz por todas”. </td></tr></table>comunica@vhir.org (VHIR)Thu, 7 May 2015 00:00:00 GMTVall d'Hebron shows to the industry the innovation carried out by Catalan hospitals and research centers (05/05/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=80&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0080\2015_0080_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> In the Catalan hospitals and research centers there are a lot of innovative ideas, but frequently don’t go any further just because their professionals are not trained in techniques of knowledge transfer. This is the point that defends the responsible of the Knowledge Transfer and Innovation Unit at Vall d’Hebron Institute of Research (VHIR), Raquel Egea, in order to explain why the knowledge transfer is still poor among the Catalan hospitals and biomedical research centers, compared to other sectors and regions. According to the data provided by the Spanish organization of patents and brands (OEPM), the applications for patents decreased by 30% in Catalonia in the last 7 years and positions the region behind others such as Madrid and Andalusia. However, if you take a look at the bibliometric indicators, Catalonia is leader in terms of visibility, excellence and cooperation in the field of biomedical research, according to a study by the Research Group on Bibliometrics. With the aim to encourage health professionals to turn their ideas into solutions, VHIR opened to all Catalan research centers and hospitals the 2nd edition of the Innovation Contest in Health. And the response was very positive because among the applicants, there are projects from Hospital Clínic, Hospital de Bellvitge, Hospital de Sant Pau, Hospital Germans Trias i Pujol, Hospital Josep Trueta, Hospital Joan XXIII, Hospital Parc Taulí, Vall d’Hebron Institut d’Oncologia (VHIO), Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), l’Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), IDIAP Jordi Gol and Institut de Recerca Biomèdica de Lleida (IRB Lleida). According to the responsible of innovation at VHIR, “the high number of applications is a success that demonstrates that hospitals and biomedical research centers have a large potential in innovation”. Now all the projects submitted are being evaluated and on May 11 will be published the finalists that will receive training in the field of knowledge transfer and innovation. Specifically, finalists will receive lessons to write a feasibility report, to know the details of the valuation process and the possibilities of funding for their projects. This training will be carried out by experts from Connecting Perspectives, Inveready, Trifermed and Barcelona Institut d’Emprenedoria. In addition, each participant will have tuition by an expert in innovation. <p style=" tex</td></tr></table>comunica@vhir.org (VHIR)Tue, 5 May 2015 00:00:00 GMTStudy identifies a key factor in the neural death that causes Parkinson's disease (29/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=77&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0077\2015_0077_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> In studying the molecular biology of brain development, a team of researchers from the Ludwig Cancer Research in Stockholm has discovered how disruption of a developmental mechanism alters the very nerve cells that are most affected in Parkinson’s disease. They have also explained how such disruption induces a lethal dysfunction in the internal, house-keeping processes of such neurons. The results of their study, in which the co-corresponding author is Dr. Ariadna Laguna, from the Neurodegenerative Diseases group at Vall d’Hebron Institute of Research (VHIR), are published in the current issue of the journal Nature Neuroscience. The study took nearly four years to complete and involved the exquisitely targeted manipulation of mouse genes to generate a unique model of the disease. According to the Ludwig Stockholm director, Thomas Perlmann, “the model, in many important ways, mimics the manifestation of Parkinson’s in humans and has illuminated what appears to be a key mechanism of neural decline in this devastating disease”. Dr. Ariadna Laguna participated in this study during her postdoctoral fellowship at the Ludwig Cancer Research. </td></tr></table>comunica@vhir.org (VHIR)Wed, 29 Apr 2015 00:00:00 GMTSurgery improves survival of women over age 80 with breast cancer (28/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=76&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0076\2015_0076_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Research Unit in Biomedicine and Translational Research in Gynecology and the Gynecological Service of the Vall d’Hebron University Hospital, led by Dr. Antonio Gil, have demonstrated that surgery is the best option to treat women over 80 years with breast cancer in early stages (I and II). The conclusion, published in the European Journal of Surgical Oncology, was obtained after comparing the evolution of 465 women with breast cancer treated in Vall d’Hebron between 1995 and 2012.&nbsp;&nbsp; Nearly the 30% of women diagnosed with breast cancer are over 80 years old and have, in most of the cases, hormonal tumors. In this situation, oncologists have two options: to operate them in order to remove the tumor, to add radiotherapy or chemotherapy and to give hormone treatment (if it’s necessary); or to administrate a primary endocrine treatment without surgery. One of the principal authors of the study, who is an associate doctor of the Gynecology Service and the Centre of Breast Cancer in Vall d’Hebron, Dr. Tomás Cortadellas, said: “physicians sometimes choose hormone therapy, the less aggressive option, just to avoid the side effects of the surgery standard treatment". Hormone therapy blocks the hormones and stops the tumor growth, but only for a few years. Specifically, researchers have shown that patients treated with hormone therapy in Vall d’Hebron presented an average of 50 months survival, while the operated women lived 109 months after the diagnosis. Besides the survival analysis in both groups, researchers observed that, in the operated group, some of them received a less aggressive surgery with suboptimal oncology results. This clinical decision neither help the patients: the ones who received an optimal surgery treatment (removal of the tumor, the sentinel node and other nodes, if it’s necessary) lived, on average, two years and a half more than the ones who received a minor surgery. At the time of doing the comparative analysis of both groups, Dr. Cortadellas studied patient’s comorbidity (that is to say, the diseases or health problems that patients also presented) to determine if their state of health could influence the treatment they received. To do this, he calculated the Charlson comorbidity index, which evaluates the patient’s life expectancy in the next 10 years. The results were homogeneous: “all the patients included in the study presented the same comorbidity, so we can compare both treatments”, said the physician. A part from this index, in order to confirm the homogeneity of the groups, he also compared other parameters like the chemotherapy and radiotherapy dose they received, the lymphovascular invasion, the tumor stage or the expression of the gene HER2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The increase in longevity requires changing the treatment <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-se</td></tr></table>comunica@vhir.org (VHIR)Tue, 28 Apr 2015 00:00:00 GMTVHIR showed at the BCN Science Festival the proteins hidden in the fruits (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=75&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0075\2015_0075_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> How many proteins are hidden in the fruits? This is the question that Miguel Aranda, researcher from the Kidney Physiopathology group at VHIR, asked to the visitors of the NOVUM Barcelona Science Festival. On Sunday morning, many children participated with their families in his workshop, located at the Plaça de les Glòries, in Barcelona, in order to know the role of the proteins in fruits and humans. The aim of Miguel’s workshop was to explain the role of proteins and why is useful to count them. In his lab, researchers study pathologies such as Dent’s disease that is characterized by the loss of proteins through the urine and leads to chronic kidney failure. The Barcelona Science Festival, which in the past editions was located at the Parc de la Ciutadella, was organized by the Barcelona city council with the aim to promote the activity carried out by research centers and scientific associations from the city. Read the poster of the workshop on this link. </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTRegistrations open for the 2nd edition of the Master's Degree in Translational Biomedical Research (27/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=27&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0027\2015_0027_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Institute of Research (VHIR), associated to the Universitat Autònoma de Barcelona, opens the registrations of the 2nd edition of the Master’s Degree in Translational Biomedical Research UAB-VHIR, which will start on October 2015. Registrations will be open until September 2015, but the first students will be admitted on April. As a new feature of this year’s edition, students will have to choose three out of the six optional subjects, taught by researchers and clinicians currently working at Vall d’Hebron University Hospital. The optional subjects are: Brain and Nervous Peripheral System Diseases; Cardiovascular and Kidney Diseases; Oncology Diseases; Liver and Digestive Diseases; Microbiology, Infectious Diseases and Critical Pathology; and Respiratory, Immune, Systemic and Endocrine System Diseases. The program will also offer new lessons on transversal competences, such as communication and outreach, business development, national and international calls, and project management. The aim of the master is to generate excellent young researchers by providing them with the necessary combination of scientific and medical knowledge and skills to contribute successfully to the future of translational medical research. It is addressed to research career, providing access to a PhD program related to the biomedicine area that the students had previously chosen for their training program and internship. In this regard, the master is an excellent occasion for working in a biomedical research laboratory with first-rate scientists and clinicians. Finally, for the second consecutive year, students will have the chance to apply for a grant that will cover all the tuition and course costs. Last year 6 students were granted, but for this second edition the number of students granted has yet to be decided. Registration process </td></tr></table>comunica@vhir.org (VHIR)Mon, 27 Apr 2015 00:00:00 GMTVHIR wins Best in Class 2014 to the best research and innovation center (24/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2014&num=226&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2014\2014_0226\2014_0226_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d'Hebron Institute of Research (VHIR) has received this morning the Best in Class award to the best research and innovation center, one of the prizes organized by the journal Gaceta Médica and the Cátedra de Innovación y Gestión Sanitaria de la Universidad Rey Juan Carlos. The Unit of transplantations of haemopoietic progenitors at Vall d'Hebron University Hospital (HUVH) and the Multiple Sclerosis Center (Cemcat) also have been awarded in a ceremony in which were represented the best hospitals of Spain. This award fits perfectly with the aim of VHIR, which mission describes it as an institution that promotes and developes not only research but also biomedical innovation. VHIR does research to improve people's lives, and its researchers work to transfer to the society the knowledge they got investigating in the&nbsp; labs. Their results don't stay in the labs, but seek to be applied in patients in mid term. Dr. Joan Comella, VHIR's director, received the award in a cerimony that took place in the World Trade Center of Barcelona with the presence of the Catalan Health Minister, Dr. Boi Ruiz. </td></tr></table>comunica@vhir.org (VHIR)Fri, 24 Apr 2015 00:00:00 GMTVHIR proposals for Sant Jordi (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=71&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0071\2015_0071_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Here you have our three recommendations for this Sant Jordi’s Day: ‘En Roc al Planeta Mascareta’, ‘Nano-Oncology, the Turning Point’ and ‘Aians’. These three books are written by professionals from Vall d’Hebron Hospital. En Roc al Planeta Mascareta Roc is a kid who after escaping from the paws of a terrible dragoon (the disease), with the help of his horse (his family), arrives to Mascareta Planet (the hospital), where he will live many adventures and many people will help him (clinicians, nurses, psicologists…). The adventures represent different phases of the disease. The authors of the book are two nurses of the Oncohematology Service, Raquel Moya and Carmen Biota, and the Acuna Patata association. The price of the tickets is 6 euros that will directly go to the research in Child Cancer at VHIR. You can buy the book on Sant Jordi’s Day from 9AM to 3.30PM in front of the maternal and child building. You can also buy it through the website of the association and by email to Dr. Miguel Segura. Nano-Oncology, the Turning Point “Far from the public perception that nanotechnology and nanomedicine are still trending topics of science fiction, a new emerging reality is deepening its roots in our society and people begins to realize that a new giant wave is going to smash our shores in the form of a technological revolution... and the impact might even go beyond imagination”, wrote Dr. Simó Schwartz, head of the CIBBIM-Nanomedicine, in the foreword of Prof. Victor Puntes’ book.&nbsp; Sharing his professional and personal experiences in the laboratory and the teaching, Dr. Puntes, who is currently working as a researcher in the CIBBIM-Nanomedicine area at VHIR, leads us in this fascinating revolution through the pages of his book. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTRecognition of the professional career of three researchers from VHIR (23/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=74&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0074\2015_0074_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr Josep Sánchez de Toledo, responsible of the group of Translational Research in Child Cancer in the Vall d’Hebron Research Institute (VHIR) and responsible of the Oncology and Child Haematology Service was awarded with the Medalla Josep Trueta. This recognition is given by the Generalitat de Catalunya with the objective of honoring professionals or entities that have stood out for the services rendered in view of progress and improving health. Dr Sánchez de Toledo combines his clinical work in children with tumors and bone marrow transplants with the most advanced research in childhood cancer. To recognize his intensive activity for the children welfare and his leading research, his research group collects donations from important entities, patients associations and citizen’s initiatives, and obtains European and Catalan competitive aids, like La Marató de TV3. New memberships of the Real Academia Médica Besides, two other researchers received also an important recognition for their work in health care and research. The Reial Acadèmia de Medicina de Catalunya designated corresponding academician the Dr. Ricard Pujol, responsible of the Immunology research group in VHIR, and Dr Santiago Ramón y Cajal, responsible of the Oncology and Pathology Molecular research group. Dr Pujol, nowadays, is combining his work in VHIR with being the responsible of the Immunology Service of the Hospital and is a research adviser of the Institut Català de la Salut (ICS). In the field of the research, professor Pujol is an international leader in the study of the autoimmune diseases, especially in the Graves disease, and either in the identification of new biomarkers to diagnose these illnesses. Dr Ramón y Cajal also shares his dedication in VHIR with being the responsible of the pathological Anatomy Service in the Hospital. In the research field, he is a pioneer in the study of the signaling pathways in human tumors, the study of the aging gene expression in tumors and the identification of therapeutic targets associated with the tumor progress and the pharmacological resistance in colorectal carcinomas. A part from this recognition, Dr Ramón y Cajal has been recently chosen member of the Real Academia Nacional de Medicina. </td></tr></table>comunica@vhir.org (VHIR)Thu, 23 Apr 2015 00:00:00 GMTCome to the Party of the Research at Vall d'Hebron (21/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=69&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0069\2015_0069_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Get it in your diary: Saturday 23rd of May, Pavelló Olímpics (in front of the University Hospital Vall d’Hebron). We have organized a lot of activities and surprises to celebrate with all the society our 20th birthday, and also as a preamble of the 60th birthday of our Hospital. This day you will see what kind of research we do in VHIR, through scientific workshops and an exhibition of amazing photographs (the winning images of the science photography competition). But especially it will be a feast day, with activities for all the family: bouncy castles, music, games for the children, dancing, magic, sports and a lot of solidarity. There will be sweepstakes, a big solidarity paella, merchandising and deep gratitude, because with these activities we want to make the society aware of the importance of the research and bring the opportunity to collaborate with the biomedical research in VHIR. The party will be amused by the Magician Andreu, the TV star Enric Company and the VHIR, our mascot! In the afternoon there will be the winning group of the last edition of the TV program Oh Happy Day!, that will perform on the Pavilion’s stage. But there will be more music: los Fugados de Alcatraz, who will sing together with the Choir of the Vall d’Hebron our song called ‘Aire’, written by Pedro Pardo and Marta Hernández, and the concerts of Manu Guix, Boxet, la Gira-sol and other special invitees. So, don’t think it twice. We want to see you on Saturday 23rd of May from 10h to 20h in the Pavelló Olímpics. You will have a nice day with surprises and discoveries! </td></tr></table>comunica@vhir.org (VHIR)Tue, 21 Apr 2015 00:00:00 GMTVall d'Hebron releases 250 balloons, one for each known primary immunodeficiency disease (20/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=66&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0066\2015_0066_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Vall d’Hebron Research Institute (VHIR) is joining, one more year, the celebration of the World Primary Immunodeficiency Week, which has the objective of increase the recognition and the diagnosis of these diseases. This year 250 ballons have been released with the collaboration of the 5th course students of the School Jesuïtes de Sant Gervasi-Infant Jesús and with the support of Designa SCP. Children diagnosed with Primary Immunodeficiency Diseases (PID) in the Hospital have also participated, with their families and clinicians. Primary Immunodediciency Diseases (PID) PID is a group that includes more than 250 different rare or minority illness caused by alterations in the immunology system of the children. They affect one in every 2.000 live newborns, and these people are susceptible to suffer severity infections that, in case of not being treated properly, could be dangerous or cause lasting damage. The early diagnosis and the research to find more effective treatments are very important to assure the patients survival and to improve their quality of live, reducing the lasting damage. Nowadays PID isn’t a sanitary priority and neither social. PID in the Vall d’Hebron Hospital The University Hospital Vall d’Hebron leads the health attention of the pediatric patients in our country, with more than 700 diagnosed patients, the 70% of the total in Catalonia, according to the figures reported by the PID European Register of the European Society for Immunodeficiency and by the Jeffrey Modell Foundation (JMF). And among them, more than 400 are under 18 years old. In VHIR, the research groups of Infection in immunocompromised pediatric patients and Immunology investigate about it. <span style=" font</td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTVHIR has obtained the HR Excellence in Research recognition (20/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=68&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0068\2015_0068_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Vall d’Hebron Research Institute (VHIR) has obtained the recognition of the European Commission HR Excellence in Research. This recognition proves that VHIR endorses the general principles of the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers (Charter &amp; Code), and firmly supports its commitment in improving internal policies and procedures. This recognition of excellence is an opportunity to establish a comprehensive and coherent Human Resources Strategy, that should allow to achieve international visibility. On March 2014, the VHIR initiated the process for the award recognition by performing a first analysis of the relevant applicable legislation and the alignment of the Institution with the Charter and Code principles. Then, specific Focus Groups were organized in order to involve all personnel and to establish priority actions: Focus Group of administration and structural personnel, Focus Group of predoctoral and postdoctoral researchers and laboratory technicians, Focus Group Tenure Track researchers and Focus Group of researchers. Thanks to the collaboration of these collectives in the Focus Groups, the project has been a very positive and enriching experience. You can find in our website the Action Plan of the accreditation for the next 4 years, and the information about the European Charter for Researchers and a Code of Conduct for the Recruitment of Researchers and the Human Resources Strategy for Researchers. </td></tr></table>comunica@vhir.org (VHIR)Mon, 20 Apr 2015 00:00:00 GMTPossible new strategies to combat epithelial metastatic cancer have been described (16/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=63&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0063\2015_0063_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> An article published by researchers from the School of Pharmacy of the University of Lisbon and from the Molecular Biology and Biochemistry Research Centre for Nanomedicine (CIBBIM-Nanomedicine) from the Vall d'Hebron Research Institute (VHIR) includes the latest discoveries in the field of epithelial metastatic cancer and considers the possibility of opening new therapeutic fronts for the treatment of the breast cancer. The article, published in the specialized magazine Current Gene Therapy, focus on the process by which epithelial cells in the body become stem cells, process known as Epithelial Mesenchymal Transition (EMT), and what gene regulation strategy could be used to control this process in tumors, reducing the dangerousness of the breast metastatic cancer. EMT is useful to conceive organs, to regenerate tissues or for the wound healing, but it also plays a very important role in metastatic cancers with an epithelial origin. In this phenomenon, epithelial cancer cells lose their morphological features, acquiring the features of an undifferentiated cell, and get the propriety to survive without being attached to other cells. In consequence, undifferentiated cells are able to detach from the epithelial tissue and travel through the blood to colonize other tissues where they establish and develop the metastasis. Many intracellular changes are necessary for this process, and they are, then, clue elements in the regulation of the tumor’s invasive and metastatic capacity. Some of these regulatory factors are presented in this article as possible therapeutic target, taking into account they have different roles in each kind of tumor and in each tumor’s evolution stage.&nbsp; According to researchers, new methods of gene therapy could allow the modification of these regulatory factors’ expression, keeping the cancer in its early stages, before they become undifferentiated, when the cancer is more sensible to the chemotherapy. This would allow control cancer’s invasive potential and raise the efficacy of the treatment because, often, cells that suffer this phenomenon don’t respond to the pharmacological therapy.&nbsp; </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTThe Association for the Familial Hypomagnesemia gives 15,000€ for the research in VHIR (16/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=65&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0065\2015_0065_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Association for the Information and the Research in Familial Hypomagnesemia (HIPOFAM) has given 15,000 euros to the Kidney Physiopatology research group of the Vall d’Hebron Research Institute (VHIR) to investigate this rare disease. With this contribution, the group leaded by Dr Anna Meseguer will hire a junior researcher who will be fully dedicated to the research in Familial Hypomagnesemia, as part of a project coordinated by Dr Gema Ariceta, responsible of the Paediatric Nephrology Service at the Vall d'Hebron University Hospital. The project, funded by the Fondo de Investigación Sanitaria, has the objective of ultrasequencing the RNAm and the microRNAs obtained from exosomes of patients with familial hypomagnesemia, hypercalciuria and nephrocalcinosis with known mutations in the claudina 19 gene. The familial hypomagnesemia affects the kidney because, due to a protein malfunction, the organ doesn’t reabsorb the magnesium. That produces the magnesium is expelled through urine and its blood level is very low. If you want, you can also contribute. </td></tr></table>comunica@vhir.org (VHIR)Thu, 16 Apr 2015 00:00:00 GMTVHIR leads an international course in sepsis and pneumonia (15/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=64&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0064\2015_0064_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Once again Vall d’Hebron brought together national and international experts in the field of sepsis and pneumonia at the International Course on Antimicrobial Strategies in Infection and Sepsis (ICASIS), hosted in Sitges on April 13th and 14th. In this year’s edition participated professionals from Germany, France, Italy, Belgium, Turkey, Portugal, Switzerland and Spain. Clinicians and researchers discussed the latest advances in innovation and management of patients with serious infections, both from bacterial and fungal origin. In a session coorganized by CIBERBNN and CIBERES , participants talked about the new molecular diagnostics techniques applied to sepsis, including PCR techniques, mass spectrometry and nanotechnology. They also presented clinical cases with innovative treatments by multiresistant bacteria, septic shock complications, and the most recent findings related to biomarkers. The course was chaired by Dr. Jordi Rello, head of the Clinical Research and Innovation in Pneumonia and Sepsis group at Vall d’Hebron Institute of Research (VHIR), and coordinated by Dr. Cristopher Mazo, researcher from the same group. The next edition will be the 30th and 31st of March of 2016 and will be devoted to sepsis in immunocompromised patients. </td></tr></table>comunica@vhir.org (VHIR)Wed, 15 Apr 2015 00:00:00 GMTRoche's world leaders visit VHIR (14/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=62&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0062\2015_0062_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Every year Roche organizes a world meeting with all its officers. Two days where the pharmaceutical giant meets to visit one of their offices and reflect on their present and future. In 2015 has arrived the moment to visit Roche Sant Cugat, in Barcelona. In this context we must understand the visit of its top leaders to Vall d'Hebron University Hospital and VHIR. During two hours, within a tight schedule of two days, Roche has decided that one of the activities of its annual meeting would be visiting our hospital and research institute. The reason is easy, Vall d'Hebron is one of the leaders of the pharmaceutical in innovative projects in our country, so that's the reason why the responsible for Roche Spain wanted to show their international colleagues the potential of the collaboration with our campus. The meeting has been chaired by the manager of HUVH, Dr. Vicente Martínez Ibáñez, and the head of research and innovation of the Catalan Ministry of Health, Gabriel Capellá. Also, Ramon Maspons, responsible of Innovation of the Health Quality and Evaluation Agency of Catalunya (AQuAS) made a presentation to inform the responsible of Roche about the data indicating the good work being done in our country related to research and innovation. On the part of Roche have been present the senior management of the Leadership Team, Roland Diggelmann, Division COO, Dan Zabrowski, Global Head Tissue Diagnostics and Jean-Claude Gottraux, Global Head Professional Diagnostics, and other regional leaders to complete twenty representatives. As to VHIR, besides its director, Dr. Joan Comella, who presented the hospital and its research, there were researchers from the liver diseases group. Represented by Dr. Josep Quer, presented a unique breakthrough that will serve to develope a new deep sequencing methodology that accurately classifies the 7 confirmed genotypes of the hepatitis C (HCV) virus, and the different subtypes. The new system also allows, for the first time, to identify infections with more than one subtype of the virus (mixed infections), the variability of the virus and possible resistance mutations. On behalf of VHIO, besides the presence of its director, Dr. Josep Tabernero, has intervened Dr. Joaquin Arribas, who presented the possible developments of diagnostic applications based on platforms of new generations of Roche, the basis of RIS3CAT project, in which are jointly working VHIR, VHIO and Roche. "It is a pleasure to visit Barcelona and being able to see first hand the full potential of the relationship between Roche and Vall d'Hebron. We were impressed to see what it's being done and what we can do together in the future," said Roland Diggelmann to close the meeting. </td></tr></table>comunica@vhir.org (VHIR)Tue, 14 Apr 2015 00:00:00 GMTThe Bangle, solidarity bracelet with childhood cancer (13/04/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=61&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0061\2015_0061_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Season's Barcelona, an online jewelry company of Sant Cugat, has launched the solidarity collection Bangle, which consists of several unisex bracelets. 100% of the profits will be for the group of translational research in childhood and adolescence cancer at Vall d'Hebron Institute of Research (VHIR). The initiative has the support of the radio Djs of Los 40 Principales show, Xavier Martinez and Ingrid Sunyer, also from Sant Cugat, who are committed to encouraging young people to contribute to this charity project. The presentation of the collection, which took place at the House of Culture of the Town Hall of Sant Cugat, was chaired by the Deputy Mayor of Citizen Services, Susanna Pellicer, who stressed that "the town hall will promote that many people can buy it and raise funds for research." The head of the research group and of Oncology and Hematology Pediatric Service at Vall d'Hebron University Hospital, Josep Sánchez de Toledo, thanked Season's Barcelona for its commitment. "We are very pleased with this initiative. The money raised will fund one of the three research lines of our laboratory," he said. Meanwhile, the two designers and owners of Season s Barcelona, Charo Álvarez and Ester Guàrdia, explained that "from the moment we founded the company wanted to be involved in helping children and being a responsible company". These jewels, made of gold or leather, cost 20 euros. The purchase can be made through the website of the company. </td></tr></table>comunica@vhir.org (VHIR)Mon, 13 Apr 2015 00:00:00 GMTDr. Bruno Garcia arrives to Barcelona after 99 days around the world in a boat (10/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=60&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0060\2015_0060_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Bruno is at home. He will have time to rest before rejoining his activity as cardiologist at Vall d'Hebron University Hospital, but yesterday, along with his brother Willy, stepped on dry land after more than 99 days on his boat, We Are Water, with which on Thursday April 9, more than 14 days after the arrival of the winner, finished fifth in the Barcelona World Race. Brothers Bruno and Willy Garcia, an example as sailors and persons were exhausted but elated, happy and satisfied a few minutes after their arrival to the Portal de la Pau, where a crowd were waiting form them on a sunny afternoon in Barcelona. "Going with my little brother has been the biggest success I could ever have. Surely there are better navigators, but I don't have a brother like him, it has been tremendous, tremendous!", assured Bruno with tears in his eyes. More than three months ago we remember the image of the presentation of the boat, the last to be prepared, but good enough to compete with the best. One day late in December, when Bruno posed with the logo of VHIR, which has showed throughout the race with pride for over 23,000 miles in which have suffered many changes in conditions. "You can't imagine how hard it is to endure these conditions with this boat, both the sea and the boat are very demanding, and we have been very fast, but those who have won us have gone even faster, because they are professionals. And I love my profession as much as sailing", says Bruno. For almost one hundred days have brought the solidarity message from We Are Water and Vall d'Hebron Institute of Research on their boat. The experience has made them appreciate the importance of these messages. "I can only say that the world is not as great as we all thought. Because if two brothers as we have been able to get around with a sailboat, which by the way is a wonder, then it's smaller than we think. And therefore, we have to care." Caring for the world and the people who inhabit it. And a message to overcome the daily difficulties. "You miss the fresh food ... a tomato would taste like the glory to me now! But then there aren't so many things that you need, the great lesson is that you can manage yourself without many things." </td></tr></table>comunica@vhir.org (VHIR)Fri, 10 Apr 2015 00:00:00 GMTVHIR talks about research on child cancer at the Live Research Fair (08/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=59&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0059\2015_0059_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Which are the differences of cancer during childhood and adulthood? Why does it take so long for the approval of new drugs? Are there any clinical trials for child cancer? These are some of the questions that the members of the Translational Research in Child and Adolescent Cancer group at VHIR have answered to the students that have visited the Ágora room at the CosmoCaixa. The museum hosts from the 8th to the 11th of April the 13th edition of the Live Research Fair, in which participate 12 Catalan research groups. At Vall d’Hebron’s stand, researchers have 3 posters in which answer some of these questions and describe the experiment that have moved from the laboratory to the fair: a cell proliferation and viability essay. In this experiment, students will test the effect of some drugs, using a simple and quick method, and check its efficacy through the microscope granted by Izasa Scientific. The fair is organized by the Parc Científic de Barcelona, with the support of Obra Social “la Caixa” and the Barcelona city council. The aim of the event is to bring science to society and promote scientific vocations among young people. Posters </td></tr></table>comunica@vhir.org (VHIR)Wed, 8 Apr 2015 00:00:00 GMTVHIR hosts a strategic workshop to implement personalized medicine in Europe (07/04/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=58&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0058\2015_0058_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Members of the PerMed European Project, called “Personalized Medicine 2020 and beyond – Preparing Europe for leading the global way”, joined at Vall d’Hebron Institute of Research (VHIR) to agree and finish the strategic research and innovation agenda to bring forward the implementation of personalized medicine for the benefit of society.&nbsp; VHIR is represented by the Instituto de Salud Carlos&nbsp; III, who leads the agenda’s work package. Personalized medicine has become an international priority and one of the most important issues of Horizon 2020, the programme of the European Comission. 27 international entities in the field of biomedical research participate in PerMed with the aim to develop the strategic agenda, implement the personalized medicine and complement existing activities by identifying and promoting promising research topics. The publication of the strategic research and innovation agenda is expected before summer. The agenda will suggest common activities and potential joint funding in relevant areas of personalized medicine research. The proposed implementation plan will point out priorities and recommend instruments and timelines for future European research policies. </td></tr></table>comunica@vhir.org (VHIR)Tue, 7 Apr 2015 00:00:00 GMTFour biomedical research centres in Barcelona join forces to bridge the gap between investigation and clinical practice (31/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=56&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0056\2015_0056_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The Centre for Genomic Regulation (CRG), the Institute for Research in Biomedicine (IRB Barcelona), the August Pi i Sunyer Biomedical Research Institute (IDIBAPS), and the Vall d’Hebron Research Institute (VHIR)—the two last institutes linked to the Clínic Hospital and Vall d’Hebron Hospital, both university training hospitals in Barcelona—have designed a training programme called “PhD for Medical Doctors – PhD4MD”. This is a pioneering initiative seeking to speed up the transfer of results generated by biomedical research activities in Spain to clinical practice—a process commonly known as translational medicine. The commitment to biomedical research in Spain over the last ten years has yielded its rewards and now several Catalan research centres are placed among the leading and most prestigious centres in Europe and worldwide. A solid framework for basic biomedical research has been slowly put together and the time is now ripe to join forces with the strong translational research undertaken in hospital in order to transfer the knowledge generate into clinical practice. In this regard, collaboration between basic research centres and hospitals is essential, as is the focus on multidisciplinary projects that include medical doctors who have received specialized training for the purpose. This is precisely what “PhD for Medical Doctors – PhD4MD” is about—a collaborative programme promoted by the Catalan centres CRG, IRB Barcelona, IDIBAPS and VHIR, in which physicians in Spain that have already completed&nbsp; their Specialised Health Training (known as MIR in Spanish) perform&nbsp; cutting-edge PhD research projects. “It is a challenge for research centres to translate their findings into clinical practice. It is crucial to further basic knowledge, but all this effort makes no sense if there is no benefit for public health”, explains Luis Serrano, director of CRG. “We need to have medical doctors who are willing to collaborate with us and to train in order to ensure that our research reaches the hospital setting”, concludes Serrano. The first call, which will serve as a pilot programme, will offer four fellowships for medical doctors that wish to be trained in research and to do a PhD over three years. Joan Comella, director of VHIR comments that, “the experience of hospitals in clinical and translational research will help basic research centres to bring their knowledge to the bedside”. In his experience, “together, medical doctors and researchers form a perfect team to improve public health”. The four participating centres will work on collaborative projects that involve a basic research group (at IRB Barcelona or CRG) and a translational or clinical research team (at VHIR or IDIBAPS). “The four centres have opened an internal call to select outstanding projects orientated to translational medicine and with objectives that can be achieved in a period</td></tr></table>comunica@vhir.org (VHIR)Tue, 31 Mar 2015 00:00:00 GMTEnvía un SMS con la palabra DIDAC al 28014 (30/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=54&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0054\2015_0054_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Desde hoy ya se puede contribuir a la investigación de las inmunodeficiencias primarias (IDPs) en el Vall d’Hebron Institut de Recerca (VHIR), enviando un mensaje con la palabra DIDAC al 28014*. El importe íntegro del SMS, 1,20€, irá destinado a la investigación de este conjunto de enfermedades raras que afectan a niños como Didac. Didac tiene 4 años y una enfermedad rara que afecta a su sistema inmunológico. Sus padres, Julia e Iván, llevan un año y medio haciendo grandes esfuerzos por recaudar fondos para que el equipo de investigadores del Vall d’Hebron pueda seguir con la investigación en inmunodeficiencias primarias, una patología que se llevó por delante la vida de Juan, el hermano de Didac, con tan solo tres años. Gracias a los donativos de muchas personas anónimas, la investigación en IDPs ha conseguido hallar la mutación que causa a Didac este defecto genético y ahora Didac podrá someterse a un trasplante de médula ósea. Con el objetivo de poder ayudar a más niños como Didac, sus padres han lanzado esta campaña de SMS Solidarios para recaudar fondos para la investigación en IDPs y sensibilizar a la sociedad sobre la gravedad de estas enfermedades del sistema inmunitario que predisponen al paciente a sufrir más infecciones de las normales y de forma más grave, llegando a producir linfomas, leucemias e incluso, la muerte. Como explica el padre de Didac, “estas enfermedades no son raras porque sean difíciles de curar, sino porque no se ha dedicado la suficiente investigación”. En concreto, los fondos que se recauden a través de esta campaña y de los donativos que se reciban para esta causa en Yo Investigo, se invertirán en la recogida y preservación de muestras de sangre extraídas en el hospital, a través del Biobanco HUVH. Con estas muestras, los investigadores podrán dar consejo genético a futuros padres, y avanzar en el estudio de los defectos genéticos que están detrás de estas enfermedades. En el Vall d’Hebron estudian las IDPs el grupo de investigación de Infección en el Paciente Pediátrico Immunodeprimido (del que forma parte el Dr. Pere Soler que está tratando el caso de Didac) y el grupo de Inmunología. Ambos gr</td></tr></table>comunica@vhir.org (VHIR)Mon, 30 Mar 2015 00:00:00 GMTAmics del VHIR fund the career of three young predoctoral researchers (25/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=53&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0053\2015_0053_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Marina Fortea, Marina Gabriel and Yoelsis García are the three young researchers that obtained the ‘Amics del VHIR’ grant thanks to the support of Amics del VHIR, who are the people that every month and every year donate for the research at Vall d’Hebron. Among the 23 candidates, VHIR selected these three students that will work and do their PhD at VHIR for the following 3 years: Marina Fortea holds a degree in Biology of the Universitat de Barcelona and a Master’s Degree in Biochemistry, Molecular Biology and Biomedicine of the Universitat Autònoma de Barcelona. She did an internship in the neuro-immuno-gastroenterology laboratory, led by Dr. Javier Santos and Maria Vicario, to carry out her master’s degree study on eosinophilic esophagitis; an inflammatory esophageal disease. Now, thanks to this grant, she will continue the study of this disease that causes stunted growth in children and a reduction of the esophageal caliber in adults, as well as difficulty swallowing. Marina Gabriel is a graduate in Biology, holds a Master’s Degree in Neurosciences by the Universitat Autònoma de Barcelona, and last year she was studying the hematopoietic development in the Edinburg University. On November 2012, she did and internship at VHIR and participated in the research line of neurorepair after stroke, led by Dr. Anna Rosell. In this lab, they study endothelial progenitor cells, which have a neurorepair potential and could be a new therapeutic approach for these patients. Yoelsis Garcia holds a degree in Biology of the Universidad de la Habana (Cuba), where he studied lipoproteins involved in heart diseases. On April, he will join VHIR, under the guidance of Dr. Matilde E. Lleonart, in order to work in a research project related to larynx cancer. The aim of the project is to distinguish the molecular and biological mechanisms that affect the population of cancer stem cells, which are the responsible of the bad prognosis and evolution of this tumor type. Apart from these three researchers, the Amics del VHIR also funded the first edition of the predoctoral grants of Casandra Riera and Luz Jubierre, who are now in their second year of the grant. The aim of the Institute is to repeat this call every year, and for that reason this week has started in the hospital the 3rd campaign to inform about the possibility of being Amic del VHIR. </td></tr></table>comunica@vhir.org (VHIR)Wed, 25 Mar 2015 00:00:00 GMTMessi involved with the new ad of the campaign 'Beat the silence. Beat Chagas' (24/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=52&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0052\2015_0052_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> After two years the first spot of the campaign ‘Beat the silence. Beat Chagas Disease’ was produced, FC Barcelona Foundation, Messi Foundation, The Global Health Program of the Health Catalan Institute (PROSICS) and the Vall d’Hebron Institute of Research (VHIR), with support from World Health Organization (WHO), have presented the second audiovisual of this project where, again, Messi is the protagonist. The continuation of this sensitization campaign is part of the global initiative ‘BeatChagas’ a project that aims to raise people, institutions and governments awareness of this disease. Chagas is an asymptomatic disease caused by a parasite and typically transmitted through insects (bugs), which usually live in the cracks of the houses in rural or peri-urban areas of Latin America. The new ad is about the congenital transmission of the disease (from mothers to children) to sensitize women in risk of being infected to do the detection tests. 5% of the pregnant women can transmit the disease to their children, but if these children are treated in their first months of life they become cured. The ad has been presented last Tuesday at the Camp Nou, within the medical conference ‘Bridges to beat Chagas collectively’ where many experts have been analyzing the latest news about this disease at the epidemiological, biomedical, psychosocial and management ambits, since Monday. Many patients and expert doctors from all around the world have participated in the Conference. Among them, Pere Albajar-Viñas, responsible of the control Chagas disease program of the WHO; Marcelo Leguizamón, responsible doctor of the Chagas project in the Leo Messi Foundation; Jordi Gómez, coordinator of the Medicine Topical and International Health Unite of the Global Health Program of the Health Catalan Institute (PROSICS) and researcher at the VHIR, and João Carlos Pinto, doctor specialized in Chagas, son a co-worker of Carlos Chagas (discoverer of the disease). At the institutional ambit, the vice president of the FC Barcelona Foundation, Ramon Pont, and the president of the Leo Messi Foundation, Rodrigo Messi, attended to the presentation. Gillette and the Hotel Princesa Sofía have also collaborated in the Conference. </td></tr></table>comunica@vhir.org (VHIR)Tue, 24 Mar 2015 00:00:00 GMTAround 200 people participated in the VHIR Open Day workshops for relatives (23/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=51&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Last Saturday 21st of March was a very special day for us. We opened our doors to the people we love to show them what do we do in Vall d’Hebron Research Institute (VHIR). Throughout the morning, around 200 relatives of our colleagues attended one of the 12 guided visits scheduled, after previous enrolment. All visits started in the Collserola building with a funny video played by children of VHIR workers. In the video they explained the important work performed by VHIR researchers, and show the facilities of the center. All tours passed through any of the following workshops organized by VHIR researchers: “Nanoparticles and tumor tissues”, organized by researchers of the CIBBIM-Nanomedecine in Drug Delivery and Targeting group “What do cells look like and how can we recognize their nucleus?”, organized by researchers of the Gynecology and Urology Biomedical Research Group. “What do lungs look like under a microscope?", organized by Dr. Maria Jesús Cruz, head of the Pneumonology group.&nbsp; “Extract DNA from strawberries!”, organized by Rosa Arjona, from the High Technology Unite. “¿What does it look like in the microscope?”, organized by Dr. Rosa Prieto, from the High Technology Unit. “Synthesis and applications of inorganic nanoparticles in diagnosis and detoxification”, organized by Dr. Víctor Puntes, head of the Nanoparticles and Pharmacokinetics group. “Murine models for investigating diabetes and obesity”, organized by Dr. David Martínez, researcher in the</td></tr></table>comunica@vhir.org (VHIR)Mon, 23 Mar 2015 00:00:00 GMTNew hope against growing threat of antibiotic resistance (19/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=50&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0050\2015_0050_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers from the Infectious Diseases group at Vall d’Hebron Research Institute (VHIR), the Infections and Antimicrobial Therapies group at the Institute for Bioengineering of Catalonia (IBEC) and the research group in Mycobacteria at the Universitat Autònoma de Barcelona (UAB) have identified a molecule with huge potential as a new type of antibacterial agent. The finding has been published in PlosOne. “During the course of infection, bacteria need to multiply inside the body, and they require active DNA synthesis to multiply”, says Dr. Eduard Torrents, who heads the Bacterial Infections: Antimicrobial Therapies group at IBEC. “By targeting the key enzyme that allows this to happen, we can inhibit the growth of various types of undesirable and disease-causing bacteria”. The molecule, known as M-HA, works as a ‘radical scavenger’ compound to inhibit ribonucleotide reductase, an essential enzyme in DNA replication and repair. It also demonstrates low toxicity in eukaryotic cells, which heralds a great improvement on existing RNR-inhibiting drugs, which are mostly used against cancer or viruses and are too toxic to be used as antibacterials. Access to effective antibiotics is essential in all health systems. Their use has reduced childhood mortality and increased life expectancy, and they are crucial for invasive surgery and treatments such as cancer chemotherapy and organ transplants. The most recent World Economic Forum Global Risks reports have listed antimicrobial resistance as one of the greatest economical and societal risks threats to human health. In addition to increased resistance to existing agents, there is a lack of new antibiotics in development, according to a study by the European Medicines Agency. The projection of 10 million deaths a year by 2050 is greater than the current annual death toll from cancer. It is in that context that Dr. Joan Gavaldà from VHIR states that <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: bold; color: #555555; background-color: transparent; text-decoration: none</td></tr></table>comunica@vhir.org (VHIR)Thu, 19 Mar 2015 00:00:00 GMTVall d'Hebron participates in the activities of the Brain Awareness Week (18/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=49&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0049\2015_0049_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Professionals from Vall d’Hebron University Hospital, together with researchers from the Neurotraumatology and Neurosurgery research group at VHIR, participate once again in the Brain Awareness Week, organized by the Institut Municipal d’Educació de Barcelona from the 16th to the 22nd of March. Students from the Institut Consell de Cent visited the center this Wednesday in order to know at first hand the task carried out by the professionals. The aim of the workshop, entitled 'Viu de prop el problema: coneix les causes i parla amb el malalt', is to explain the traumatic brain consequences that people can suffer after surviving a traffic accident. In this session, students learned the mechanisms involved in traumatic brain injuries, what happens in the acute phase of this event, and which are the symptoms and the social and familiar consequences that these accidents cause. During the visit, students visited the Intensive Care Unit of the Neurotraumatology and Rehabilitation service, where they saw and heard about the experience of some patients. Apart from this activity, Dr. Àlex Rovira, head of the Magnetic Resonance and Neuroradiology group, also participated in the Brain Awareness Week with a talk about the historical development of the imaging techniques of the brain in medicine. One week to raise awareness on science 21 research centers located in Barcelona collaborate with the activities of the Brain Awareness Week, in which are participating 1.200 students from 26 schools and high schools of the Catalan capital. The Brain Awareness Week is held in more than 80 countries and is promoted by the Dana Alliance for Brain Initiatives. </td></tr></table>comunica@vhir.org (VHIR)Wed, 18 Mar 2015 00:00:00 GMTAdolescents with ADHD resistant to medication reduce symptoms after a psychological treatment in group (17/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=47&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0047\2015_0047_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Researchers of the group of Psychiatry, Addiction and Mental Health of the Vall d'Hebron Institute of Research (VHIR) have reduced the symptoms of adolescents medicated for Attention Deficit Hyperactivity Disorder (ADHD) using a cognitive-behavioral group therapy. The results of psychological treatment have been published in the most prestigious journal in the field of youth psychiatry, the Journal of the American Academy of Child and Adolescent Psychiatry. The study led at VHIR was held at the Vall d'Hebron University Hospital and the Hospital Clinic between April 2012 and May 2014 on 119 adolescents between 15 and 21 years, treated with either of the two drugs used with ADHD. All patients continued with medication, but about half received cognitive behavioral therapy, and the rest simply continued with routine visits to psychiatry. At the end of the psychological treatment, which consisted of 12 group sessions of one hour a week, the symptoms of the disorder were reduced in these young people. "With the cognitive behavioral group treatment we can reduce the symptoms of adolescents with severe ADHD, especially those regarding the inattention and impulsivity," said Dr. Josep Antoni Ramos Quiroga, study director and program coordinator of ADHD at Vall d'Hebron University Hospital. According to the VHIR researcher, psychological treatment makes sense because "medication can increase the ability of patients to maintain and make better care and reduce impulsivity; but the drug does not help them get organized enough". The aim of the psychological treatment was precisely to provide teenagers strategies and skills to compensate for their symptoms, whether cognitive or behavioral. 12 sessions were divided into two modules, directed by Raquel Vidal, Rio Hortega researcher at VHIR at the time of the study and clinical psychologist at the Vall d'Hebron University Hospital. In the first module she offered strategies to control impulsivity: self-control techniques, identification of triggers and warning signs to regulate anger, interpersonal skills to accept criticism, handling frustration and motivational strategies. On the other hand, in the second module she focused on techniques for maintaining attention: strategies for planning, problem solving and decision making, ability to postpone events and skills to reduce distractions and distracting thoughts. All the techniques used were collected in the first part of the book "Cognitive-behavioral Treatment for Adolescents with ADHD and cannabis, published in 2014. ADHD is a neurodevelopmental disorder that affects between 3 and 5% of the population during childhood, and remains more than half of the patients during adolescence. The most common symptoms are inattention, disorganization, lack of impulse control, emotional instability, hyperactivity, and even oppositional defiant symptoms. Persistent ADHD in adolescence is associated with a poor academic performance, difficulties in maintaining relationships, drug abuse and risk driving and sex. <span style=" font-size: 8pt; font-family: 'Verdana', 'Geneva', sans-serif; font-style: normal; font-weight: </td></tr></table>comunica@vhir.org (VHIR)Tue, 17 Mar 2015 00:00:00 GMT42 km of effort to promote research (17/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=48&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0048\2015_0048_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Sport helps health and also research. One example was the 37th Zurich Barcelona Marathon held on Sunday. Over 42 km race, that Dr. Cristina Solé and a group of parents of the AMPA of the Virolai School proposed achieve in order to raise money for research. Dr. Cristina Solé, who investigates about Lupus Disease in the Systemic Diseases research group of Vall d'Hebron Research Institute (VHIR), raised 1,600 Euros that will be invested in research about this serious disease of the immune system. Specifically, the money will serve to fund some research projects of the internal medicine research line, in Lupus, at VHIR, a group led by Dr. Jose Ordi-Ros which has the collaboration of the Catalan Lupus Foundation and the A. Bosch Foundation. This research group works hard to find ways to treat this disease, that only in Catalonia, is affecting more than 6,000 people. With a similar purpose, a group of parents of the AMPA of the Escola Virolai also ran this marathon, but in this case, with the aim of raising funds for research in pediatric liver transplants. They raised 2,410 Euros, long surpassing the figure of 1,200 Euros that was proposed in the beginning. In both cases the challenge was a success: they all could finish the marathon and raise the money they had purposed. We congratulate them for the effort and their altruism! </td></tr></table>comunica@vhir.org (VHIR)Tue, 17 Mar 2015 00:00:00 GMTSuccess of the 4th Gut Microbiota for Health Summit (16/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=46&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0046\2015_0046_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> On 14 and 15th March was held in Barcelona the 4th Gut Microbiota for Health Summit. The event brought together more than 300 international experts (including doctors and nutritionists) and has served to expose the latest findings in the investigation of the intestinal microbiota and its importance to human health. The role that bacteria inhabiting our gut have is just beginning to be known, but it is becoming evident that there is a relationship between our microbiota and our health. "It's a fascinating and very promising area of scientific research", said Dr. Francisco Guarner, member of the physiology and pathophysiology group at VHIR and chairman of the scientific committee of the Summit. Dr. Guarner explained there are disorders that may be associated with certain intestinal microbiota, such as obesity, certain metabolic and autoimmune disorders (such as celiac disease and food allergies) or some cancers. In the Congress, organized by the UEG (United European Gastroenterology Federation) and the AGA (American Gastroenterological Association), various topics within the field of intestinal microbiota were exposed, but perhaps one of the most important was what might be the consequences of the use of oral antibiotics for the intestinal microbiota. "Every time we take antibiotics by mouth is like a forest fire in our gut occurs. We can rebuild this ecosystem, but it will take time and will never be what it was", explains Dr. Fernando Azpiroz, president of the Summit organizing committee and head of the physiology and pathophysiology group at VHIR. Other topics discussed were the relationship between gut microbiota and development of some psychiatric or behavioral disorders, such as autism; the implication of some intestinal bacteria in the cancer of colon and liver; how cant he type of delivery or the breastfeeding may affect the intestinal microbiota of children (and therefore their health), or what was the microbiota of our Paleolithic ancestors like. The Summit also discussed the use of prebiotics and probiotics to fight disorders of the intestinal flora and as a treatment for certain diseases, and the importance of a balanced diet to protect the body from many diseases. "There has been a lot of interaction between scientists and clinicians, and much discussion about what we know and what these issues can contribute in the future to improve medical practice"<span style=" font-size: 8pt; font-family:</td></tr></table>comunica@vhir.org (VHIR)Mon, 16 Mar 2015 00:00:00 GMTVHIR's Innovation Contest arrives to other research centers of Catalonia (12/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=36&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0036\2015_0036_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Today March 12 has been opened the 2nd Innovation Contest. In this editiion the great news is that, after the success of the first edition, there will be participants from Hospitals and research centers belonging to ICS, Hospital research centers of Catalonia accredited by ISCIII and Hospital research centers of Catalonia that are part of ITEMAS. Organized by VHIR in collaboration with ACC10 and ROCHE Diagnostics, the contest aims to promote the innovation that comes from hospitals and their associated research centres. With this initiative we aim to raise awareness about health innovation projects, in order to attract investors and companies. At the same time we support the projects in the first stages, where we will assess the technical viability and the market. In addition, we want to award the professionals for their innovation capacity. VHIR's Director, Dr. Joan Comella, opened the contest highlighting that "it's a unique opportunity for doctors and researchers to innovate in their field, thanks to the companys and first level tutors that will help us in this experience." He thanked the technical committee, the team of tutors and teachers for supporting this second edition. The Head of Projects and Innovation of Roche Diagnostics, Dr. Carlos Manchado, has explained why they bet for this contest, which, according to the Innovation Director at the Institute of Catalan Health (ICS), Dr. Navas, "is a model that ICS wants to estimulate". Furthermore, the Manager of Technology Transfer of ACCIÓ, Ana Simon, said that "VHIR is a reference in innovation and for this reason ACCIO encourages all the Catalan hospitals and research projects to participate." Dr. Gabriel Capellà, who presided the event as responsible for research and innovation at the Catalan Health Department, also encouraged the public institutions to bet for the innovation, as VHIR does. Closing the opening, Montserrat Llinàs presented the situation of the project 'Automatización de lavoados vesicales contínuos', awarded in the first edition of the contest. She was presented by Maria Ángeles Barba, head of Nursing at Vall d'Hebron. Angel Alonso, general manager of Vecmedical, explained why and how this company is helping this project as an industrial partner. HOW TO APPLY <p style=" text-align: left; text-indent: 0px; padding: 0px 0px 0px 0px; margin:</td></tr></table>comunica@vhir.org (VHIR)Thu, 12 Mar 2015 00:00:00 GMTThe Gynecology and Urology Biomedical Research groups collaborate with scientific teaching at the Institute 4Cantons (11/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=44&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0044\2015_0044_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The groups of Biomedical Research in Gynecology and Urology of VHIR have initiated an educational action in collaboration with the Institute Quatre Cantons (4Cantons) of Poblenou, Barcelona. This is a public secondary school with a great teaching quality and an innovative method, and therefore it was awarded the prize Ciutat de Barcelona in Education. His pedagogical project is based on finding centers of interest and introduce different subjects through them, using what they call globalized work. During this semester, the Gynecology and Urology Biomedical Research groups have offered a globalized work focused on the study of gynecologic cancers. They have proposed students to design a tool that helps researchers to investigate animal models, using their knowledge in design and digital printing. More specifically, the aim for the students is to design a mechanism for dispersing human tumors, reducing its size to introduce them in mice and investigate. During these four weeks the collaboration lasts, researchers and students meet at the premises of 4Cantons Institute to have lessons related to cancer and at the VHIR, to know the center, see in situ what the reseearch is and to do experiments. This collaboration is possible thanks to the interest that all members of the research group have for teaching, and is included within the overall objective of bringing science to society. As one of the researchers of the Ginecology group said, Dr. Anna Santamaria: "For our groups it has been a very enriching experience that has allowed us not only to bring our research to adolescents of this institute, but also encourage the researcher spirit that surely is inside some of them! ". Students are also really enjoying the experience and highlight the interest that has taken them to see up close how a prestigious research laboratory works. They tell us they have learned a lot about cancer and physiology of the body, and add: "and the best of all is that we have not only learned but may have helped research". </td></tr></table>comunica@vhir.org (VHIR)Wed, 11 Mar 2015 00:00:00 GMT'Music has an amazing ability to thrill' (09/03/2015)http://www.vhir.org/salapremsa/mitjans/mitjans_detall.asp?Idioma=en&any=2015&num=40&RSS=1&mv1=5&mv2=1<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0040\2015_0040_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> Dr Miguel Vila, head of the neurodegenerative diseases group, talked about his two passions, music and research, in an interview with la Gaceta Médica. This researcher of Parkinson's Disease at Vall d'Hebron Institute of Research (VHIR) plays for many years the violin and is a member of the medical world orchestra, that organize charity concerts over the world. In the interview in la Gaceta Médica he said that "music has an amazing ability to thrill, as for example, people with Alzheimer's disease, who can’t recognise people of their family, can feel thrilled with the music they liked". In his research field, Dr. Vila is optimistic about the chances of finding, in a not so distant future, a cure for Parkinson "as neurodegenerative diseases share common mechanisms, progress in one of these diseases contributes to the advancement of the rest. In particular, in the field of Parkinson's disease, the research is approaching to the early detection and I think that sooner or later, we will get a cure." </td></tr></table>comunica@vhir.org (VHIR)Mon, 9 Mar 2015 00:00:00 GMTVHIR coordinates a project to obtain stroke biomarkers (06/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=39&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0039\2015_0039_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The neurovascular diseases group at VHIR, led by Dr. Joan Montaner, will coordinate in the next two years the project 'Device point of care of stroke diagnostic with plasmatic biomarkers: 2-stroke-chip (TECH-StrokeChip2), funded by Instituto de Salud Carlos IIII (ISCIII). TECH-StrokeChip-2 counts with the participation of several Catalan hospitals: Vall d'Hebron, Josep Trueta, Joan XXIII, Germans Trias i Pujol, Bellvitge, Parc Taulí and Verge de la Cinta. The target of the project is to obtain panels of biomarkers for its clinical application in ictus and its introduction in a Point of Care (POC) device to be applied in the clinical practice in months or few years after the end of the study. In order to get it, they will use the serum bank of patients generated by Dr. Montaner's group, where will screen aptamers to find new biomarkers to diagnose stroke. Together with other biomarkers already identified by the Neurovascular diseases group in previous multicenter studies with the same participants hospitals, the project wants to obtain panels of biomarkers with predictive capacity for diagnostics and prognostics of stroke patients. These candidate biomarkers are integrated in a device of quick mesure based in electrochemical biosensors that will be developed at Dr. Eva Baldrich's lab in the Nanomedicine area, and will be proved in a pilot trial in some of the hospitals members of the project.&nbsp; "With this study we should be able to transfer to the patient a device that could predict diagnostics and prognositcs of stroke, which would be a major advance for all the people who's suffering this disease", comments Dr. Montaner. All the participants of TECH-StrokeChip2 had a kick-off meeting at VHIR recently which served to initiate the work that could led them to get the goals in the next two years. </td></tr></table>comunica@vhir.org (VHIR)Fri, 6 Mar 2015 00:00:00 GMTGreat success of the 1s Innovation Day organized by ICS (05/03/2015)http://www.vhir.org/salapremsa/noticies/noticies_detall.asp?Idioma=en&any=2015&num=38&RSS=1&mv1=5&mv2=3<table><tr><td><img src="http://www.vhir.org/DDGRecerca\COMUNICACIOEXTERNA\2015\2015_0038\2015_0038_IMATGE.jpg" alt="fitxa noticia" class="image" /></td><td style="font-family: Verdana, Arial, Helvetica, sans-serif;font-size: 13px;color: #000000;"> The experience “Preoperatorio online, enfermería y anestesia”, presentaded by Domingo Blanco, head of the Anesthesia Service at Viladecans Hospital has been awarded as the Best Innovative Experience of Catalan Institute of Health (ICS). This project develops a presurgery circuit, led by the nurse team at the Anesthesia Service, using the TIC to save duplicity of complementary trials and reduce movements of the patients. More than 600 people attended the 1st Innovation Day of ICS, that during all the morning have listened the 10 finalist proposals out of 388 accepted. 3 of them were from VHIR: "Neuroprotección como tratamiento de la retinopatía diabética: del modelo experimental al ensayo clínico", led by Dr. Rafael Simó, head of the Diabetes research group at VHIR and one of the winners of the first edition of VHIR Innovation Contest last year. "Desarrollo de una nueva plataforma de subtipificación de alta resolución y detección de infecciones mixtas y mutaciones de resistencia del virus de la hepatitis C", led by Dr. Joan Ignasi Esteban Mur, from the liver diseases group and "Programa de rehabilitación cardíaca y prevención secundaria en enfermos con síndrome coronaria aguda atendidos en el HUVH", led by Dr. Xavier Armengol, from the cardiocirculatory pathology group completed the presence of Vall d'Hebron researchers. On March 12 it will be the Opening of the Second VHIR innovation contest, that in this edition includes participants from other centers at ICS, Catalan centers of ITEMAS and Catalan centers accredited by ISCIII. </td></tr></table>comunica@vhir.org (VHIR)Thu, 5 Mar 2015 00:00:00 GMT